Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 6.35 Delayed Data As of Sep 30 |  +0.09 / +1.44%Today’s Change | 4.39 Today|||52-Week Range 10.85 | -19.62% Year-to-Date |
Latest MACK News | Press Releases
| Bullish and Bearish Reversals for the Week Sep 26 / TheStreet.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.26 |
| Today’s open | 6.30 |
| Day’s range | 6.20 - 6.48 |
| Volume | 3,279,464 |
| Average volume (3 months) | 2,178,452 |
| Market cap | $820.7M |
| Dividend yield | -- |
Data as of 4:14pm ET, 09/30/2016
Growth & Valuation
| Earnings growth (last year) | -66.25% |
| Earnings growth (this year) | +18.14% |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | -13.14% |
| P/E ratio | NM |
| Price/Sales | 9.86 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ADROAduro Biotech Inc | +0.39 | +3.24% |
| CLLSCellectis SA | +0.01 | +0.04% |
| INSYINSYS Therapeutics I... | -0.29 | -2.40% |
| AMPHAmphastar Pharmaceut... | +0.13 | +0.69% |
Data as of 4:00pm ET, 09/30/2016
Financials
| Next reporting date | November 7, 2016 |
| EPS forecast (this quarter) | -$0.23 |
| Annual revenue (last year) | $89.3M |
| Annual profit (last year) | -$148.0M |
| Net profit margin | -165.76% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Head- Corporate Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
